Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 266

1.

Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.

Jacka B, Bray B, Applegate TL, Marshall BD, Dias Lima V, Hayashi K, DeBeck K, Raghwani J, Harrigan PR, Krajden M, Montaner J, Grebely J.

J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12758. [Epub ahead of print]

PMID:
28719060
2.

Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa?

Lee GQ, McCluskey S, Boum Y 2nd, Hunt PW, Martin JN, Bangsberg DR, Gao X, Harrigan PR, Haberer JE, Siedner MJ.

J Acquir Immune Defic Syndr. 2017 Jun 19. doi: 10.1097/QAI.0000000000001487. [Epub ahead of print]

PMID:
28639996
3.

Patterns of transmitted drug resistance and virological response to first-line antiretroviral treatment among HIV-positive people who use illicit drugs in a Canadian setting.

Socías ME, Nosova E, Kerr T, Hayashi K, Harrigan PR, Shoveller J, Montaner J, Milloy MJ.

Clin Infect Dis. 2017 May 6. doi: 10.1093/cid/cix428. [Epub ahead of print]

PMID:
28482025
4.

Emergent drug resistance with integrase strand transfer inhibitor-based regimens.

Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, Toy J, Akagi L, Lima VD, Guillemi S, Montaner JSG, Barrios R.

AIDS. 2017 Jun 19;31(10):1425-1434. doi: 10.1097/QAD.0000000000001494.

PMID:
28375875
5.

Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.

Nosyk B, Zang X, Min JE, Krebs E, Lima VD, Milloy MJ, Shoveller J, Barrios R, Harrigan PR, Kerr T, Wood E, Montaner JSG.

Lancet HIV. 2017 Jul;4(7):e303-e310. doi: 10.1016/S2352-3018(17)30045-0. Epub 2017 Mar 30.

PMID:
28366707
6.

Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion.

Leung JM, Fishbane N, Jones M, Morin A, Xu S, Liu JC, MacIsaac J, Milloy MJ, Hayashi K, Montaner J, Horvath S, Kobor M, Sin DD, Harrigan PR, Man SF.

Aging (Albany NY). 2017 Feb 23;9(3):687-705. doi: 10.18632/aging.101184.

7.

Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification.

Lima VD, Wang L, Brumme C, Wu L, Montaner JS, Harrigan PR.

PLoS One. 2017 Feb 2;12(2):e0171155. doi: 10.1371/journal.pone.0171155. eCollection 2017.

8.

Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.

Knox DC, Anderson PL, Harrigan PR, Tan DH.

N Engl J Med. 2017 Feb 2;376(5):501-502. doi: 10.1056/NEJMc1611639. No abstract available.

9.

Identification of small molecule modulators of HIV-1 Tat and Rev protein accumulation.

Balachandran A, Wong R, Stoilov P, Pan S, Blencowe B, Cheung P, Harrigan PR, Cochrane A.

Retrovirology. 2017 Jan 26;14(1):7. doi: 10.1186/s12977-017-0330-0.

10.

HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.

Gozlan Y, Ben-Ari Z, Moscona R, Shirazi R, Rakovsky A, Kabat A, Veizman E, Berdichevski T, Weiss P, Cohen-Ezra O, Lurie Y, Gafanovich I, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Zuckerman E, Carmiel-Haggai M, Nimer A, Hazzan R, Maor Y, Kitay-Cohen Y, Shemer-Avni Y, Kra-Oz Z, Schreiber L, Peleg O, Sierra S, Harrigan PR, Mendelson E, Mor O.

Antivir Ther. 2017 Jan 9. doi: 10.3851/IMP3123. [Epub ahead of print]

PMID:
28067632
11.

Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.

Harris M, Ganase B, Watson B, Hull MW, Guillemi SA, Zhang W, Saeedi R, Harrigan PR.

HIV Clin Trials. 2017 Jan;18(1):39-47. doi: 10.1080/15284336.2016.1271503. Epub 2017 Jan 9.

PMID:
28067119
12.

Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication.

Shkreta L, Blanchette M, Toutant J, Wilhelm E, Bell B, Story BA, Balachandran A, Cochrane A, Cheung PK, Harrigan PR, Grierson DS, Chabot B.

Nucleic Acids Res. 2017 Apr 20;45(7):4051-4067. doi: 10.1093/nar/gkw1223.

13.

Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa.

Penrose KJ, Wallis CL, Brumme CJ, Hamanishi KA, Gordon KC, Viana RV, Harrigan PR, Mellors JW, Parikh UM.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01805-16. doi: 10.1128/AAC.01805-16. Print 2017 Feb.

14.

In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach.

Rahimi A, Anmole G, Soto-Nava M, Escamilla-Gomez T, Markle T, Jin SW, Lee GQ, Harrigan PR, Bangsberg DR, Martin J, Avila-Rios S, Reyes-Teran G, Brockman MA, Brumme ZL.

J Virol Methods. 2017 Feb;240:32-41. doi: 10.1016/j.jviromet.2016.11.004. Epub 2016 Nov 16.

PMID:
27865749
15.

Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort.

Tanner Z, Lachowsky N, Ding E, Samji H, Hull M, Cescon A, Patterson S, Chia J, Leslie A, Raboud J, Loutfy M, Cooper C, Klein M, Machouf N, Tsoukas C, Montaner J, Hogg RS; Canadian Observation Cohort (CANOC) Collaboration.

BMC Infect Dis. 2016 Oct 21;16(1):590.

16.

An assessment of the relationship between the World Health Organization HIV drug resistance early warning indicators and HIV drug resistance acquisition.

St-Jean M, Harrigan PR, Sereda P, Montaner J, Lima VD.

HIV Med. 2017 May;18(5):342-353. doi: 10.1111/hiv.12435. Epub 2016 Oct 4.

PMID:
27704659
17.

NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain.

Jimenez-Sousa MÁ, Gutiérrez-Rivas M, Álvaro-Meca A, García-Álvarez M, Harrigan PR, Fedele CG, Briz V, Vázquez-Morón S, Resino S.

PLoS One. 2016 Sep 29;11(9):e0163197. doi: 10.1371/journal.pone.0163197. eCollection 2016.

18.

Increasing prevalence of K65K and K66K in HIV-1 subtype B reverse transcriptase.

Telwatte S, Brumme CJ, Hearps AC, Latham CF, Hayward JA, Sonza S, Sluis-Cremer N, Harrigan PR, Tachedjian G.

AIDS. 2016 Nov 28;30(18):2787-2793.

PMID:
27677159
19.

A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure.

Gonzalez-Serna A, Swenson LC, Watson B, Zhang W, Nohpal A, Auyeung K, Montaner JS, Harrigan PR.

Clin Microbiol Infect. 2016 Dec;22(12):1004.e9-1004.e16. doi: 10.1016/j.cmi.2016.08.012. Epub 2016 Aug 30.

PMID:
27585940
20.

Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010.

Buchacz K, Lau B, Jing Y, Bosch R, Abraham AG, Gill MJ, Silverberg MJ, Goedert JJ, Sterling TR, Althoff KN, Martin JN, Burkholder G, Gandhi N, Samji H, Patel P, Rachlis A, Thorne JE, Napravnik S, Henry K, Mayor A, Gebo K, Gange SJ, Moore RD, Brooks JT; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA.

J Infect Dis. 2016 Sep 15;214(6):862-72. doi: 10.1093/infdis/jiw085. Epub 2016 Apr 18.

PMID:
27559122

Supplemental Content

Loading ...
Support Center